Current therapeutic strategies used to mitigate the impact of toxic misfolded proteins and aggregates in the context of ALS include: (1) lowering SOD1 protein levels to reduce the extent of its aggregation; (2) using the RNAi method to degrade mutant mRNA; (3) using antibodies to degrade mutant protein species; and (4) using genome editing techniques to correct the mutated nucleotide. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.